BPC-157 vs TB-500: Research Differences Explained

Evidence at a glance

Preclinical only, both

Neither peptide has a published human trial, so this is a comparison of animal literature. That is exactly why the two bodies of work are worth separating.

Why researchers are interested

They are studied for different parts of repair. BPC-157 dominates tendon, ligament and gastrointestinal models. Thymosin beta-4 dominates cell migration and dermal wound closure. Neither is a substitute for the other in the research record.

What the research found

BPC-157, tendon and soft tissueIncreased fibroblast outgrowth, survival and migration in culture
BPC-157, gastrointestinal protectionLess mucosal damage in rodent injury models, its largest literature
TB-500, wound closureFaster healing in animal and cell wound models
TB-500, cell migrationPromoted migration and angiogenesis through actin regulation

Reported in the literature

Neither compound has controlled human safety data.
Neither is approved by any medicines regulator.
Both are prohibited in competitive sport under the WADA Prohibited List.

Findings are summarised from the sources listed under References on this page, and from approved product labelling where a compound has one. These are outcomes observed in published studies, not effects claimed for any person, and nothing here is a recommendation for human use.

All research guides

BPC-157 and TB-500 are the two most-studied peptides in tissue-repair research, routinely compared and routinely sold together. They are not variants of one another: they are different molecules acting through different mechanisms, and the reason they are paired is that those mechanisms are separate. This guide covers the identity of each, how the mechanisms differ, what the literature actually examined, and how the evidence bases compare. It is written for researchers and is not medical guidance.

Research-use note: both compounds are supplied strictly for laboratory research. They are not supplements and not for human or animal consumption. Every finding below comes from cell-culture or animal-model work.

Identity

Values checked against PubChem on 2 October 2026.

Property	BPC-157	TB-500 / thymosin β4
Type	Synthetic pentadecapeptide, 15 residues	Fragment related to thymosin β4, a 43-residue protein
CAS	137525-51-0	77591-33-4
PubChem CID	9941957	16132341
Formula	C₆₂H₉₈N₁₆O₂₂	C₂₁₂H₃₅₀N₅₆O₇₈S
Molar mass	1419.5 g/mol	4963 g/mol
Origin of sequence	Partial sequence of a protein in gastric juice	Naturally occurring actin-binding protein

One caveat on the TB-500 row. CAS 77591-33-4 resolves to full-length thymosin β4, not to the shorter fragment usually sold as TB-500. The material traded under the TB-500 name is commonly the actin-binding fragment rather than the whole 43-residue protein. That is a meaningful difference in molar mass, so confirm which form a specification describes before computing concentrations, and treat the CAS as naming the parent molecule.

Two different mechanisms

This is the part that actually matters, and it is usually reduced to “both help tissue repair”, which explains nothing.

Thymosin β4 is an actin-binding protein. The literature describes it as the major G-actin-sequestering protein in mammalian cells — it binds monomeric actin and regulates how readily that actin assembles into filaments. Actin filaments are the internal scaffolding a cell rebuilds in order to change shape and move. That is why the TB-500 literature is a literature about cell migration: the proposed mechanism is upstream of a cell’s ability to relocate.

BPC-157 has no single agreed mechanism. Work in animal models has proposed modulation of growth-factor signalling, interaction with the nitric-oxide pathway, association with VEGFR2 in angiogenesis studies, and influence on collagen organisation. These are competing hypotheses about observed effects, not an established pathway, and the research is concentrated in localised tissue and gastrointestinal models.

So the contrast is: one compound is studied around a defined molecular activity (actin sequestration) with motility as the consequence; the other is studied around observed effects in injury models with the mechanism still open.

How the evidence bases compare

They are not equivalent, and the difference is worth knowing before citing either.

Thymosin β4 is a naturally occurring protein with a broad, independent literature across cell biology, and its actin-sequestering role is well established and widely reproduced.

The BPC-157 literature is larger in volume on the specific compound but far more concentrated: a substantial share comes from a small number of closely associated research groups, mostly in rodent models, with no substantial published human clinical trial literature. Volume of citations is not the same as independent replication.

Why they are studied together

Because the mechanisms are separate rather than overlapping. Pairing them lets a protocol examine localised tissue-repair signalling alongside actin-mediated cell migration in the same model, which is the rationale behind the Wolverine Stack, and why both also appear in the four-peptide KLOW blend alongside GHK-Cu and KPV.

The cost of a blend is attribution. With both compounds in one vial, a result cannot be assigned to either, and the two cannot be varied independently. A study designed to separate their contributions needs the single compounds.

Which compound suits which question

Cell migration, motility, or actin dynamics — TB-500 / thymosin β4 is the compound with the defined mechanism and the broader independent literature.
Localised soft-tissue or gastrointestinal injury models — BPC-157 has the deeper compound-specific literature, with the caveat about concentration above.
Both pathways in parallel — the combined blend, accepting that attribution is lost.

What the research examined

BPC-157: Chang et al. (J Appl Physiol, 2011) examined tendon fibroblast outgrowth, survival and migration in cultured cells. Sikiric et al. (Curr Pharm Des, 2011) reviewed the gastrointestinal model work. See our BPC-157 research guide.
TB-500 / thymosin β4: Malinda et al. (J Invest Dermatol, 1999) reported accelerated wound healing in animal models. Philp and Kleinman (Ann N Y Acad Sci, 2010) reviewed the animal-model work on it as a multifunctional tissue-repair peptide.

These findings describe outcomes in laboratory models, not validated outcomes in humans.

For research use only

All products and information referenced here are intended strictly for laboratory and scientific research use only. They are not for human or animal consumption and are not drugs, foods, supplements, or medical devices. Nothing here should be interpreted as medical advice, and no outcome in a person is described, implied or promised. Products are supplied against a stated purity specification.

Shop these research peptides

BPC-157 10 mg — standalone
Wolverine Stack (BPC-157 + TB-500) — both compounds combined
KLOW 80 mg — four-peptide blend including both
Full research catalog

Common questions about BPC-157 vs TB-500

Is TB-500 the same as thymosin beta-4?

Not exactly. Thymosin beta-4 is a naturally occurring 43-amino-acid actin-binding protein. TB-500 is a synthetic peptide related to it, and most of the published research was done on thymosin beta-4 itself.

Can BPC-157 and TB-500 be bought together?

Yes. The Wolverine Stack combines BPC-157 and TB-500 in one vial, and KLOW contains both plus GHK-Cu and KPV. BPC-157 is also sold on its own.

What is the main research difference between them?

BPC-157 is studied mostly in tendon, muscle and gastrointestinal models. Thymosin beta-4 is studied around actin regulation, cell migration and wound healing. Both bodies of work are preclinical.

References

Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol. 2011. PubMed
Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011. PubMed
Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. PubMed
Philp D, Kleinman HK. Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2010. PubMed
Compound identity verified against the PubChem database, retrieved 2 October 2026. PubChem